Monocytes Prime Autoreactive T cells After Myocardial Infarction.
In humans, loss of central tolerance for the cardiac self-antigen, α-myosin heavy chain (αMyHC), leads to circulation of cardiac autoreactive T cells and renders the heart susceptible to autoimmune attack after acute myocardial infarction (MI). MI triggers profound tissue damage, releasing danger signals and self-antigen by necrotic cardiomyocytes, which leads to recruitment of inflammatory monocytes. We hypothesized that excessive inflammation by monocytes contribute to the initiation of adaptive immune responses to cardiac self-antigen. Using an experimental model of MI in mice, αMHC-mCherry reporter mice, which specifically express mCherry in cardiomyocytes, we detected αMyHC antigen in myeloid cells in the heart-draining mediastinal lymph node (MLN) 7 days after MI. To test whether monocytes were required for cardiac self-antigen trafficking to the MLN, we blocked monocyte recruitment with a CCR2 antagonist or immune modifying nanoparticles (IMP). Blockade of monocyte recruitment reduced αMyHCantigen detection in the MLN after MI. Intramyocardial injection of the model antigen, ovalbumin, into OT-II transgenic mice demonstrated the requirement for monocytes in antigen trafficking and T-cell activation in the MLN. Finally, in non-obese diabetic mice, which are prone to post-infarction autoimmunity, blockade of monocyte recruitment reduced αMyHC-specific responses leading to improved tissue repair and ventricular function 28 days after MI. Taken together, these data support a role for monocytes in the onset of pathological cardiac autoimmunity following MI and suggest that therapeutic targeting of monocytes may mitigate post-MI autoimmunity in humans.